Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million

Privium Fund Management reduced its Arrowhead Pharmaceuticals position by 75,747 shares in Q4 (SEC filing Feb. 2), an estimated $3.71 million trade, leaving 398,204 shares valued at $26.44 million and representing 4.87% of its 13F U.S. equity AUM. Arrowhead shares were $73.00 as of Feb. 2, up ~289.5% year-over-year after FDA approval of REDEMPLO; fiscal 2025 revenue jumped to $829.45 million (from $3.6 million) and operating income swung to a $98 million profit, so the sale reads as risk management rather than a loss of conviction.

Analysis

Market structure: Arrowhead (ARWR) is a clear short-term winner — approval-driven revenue jumped to $829M TTM and the stock is +289% Y/Y, tightening funding spreads for RNAi peers and increasing bargaining power with big pharm partners. Privium's $3.7M trim (75,747 shares) is small relative to its remaining $26.4M stake (4.87% of AUM) and looks like risk-management not a negative signal; expect continued retail/institutional rotation into approved-RNAi names and elevated equity/option flow into ARWR.

Risk assessment: Tail risks include regulatory reversals (label/REMS changes), CMC/manufacturing scale failures, or loss of milestone streams from partners — any single adverse event could cut market cap >30% given earnings concentration and lumpy milestone revenue. In days–weeks, price will be driven by selling pressure if 13Fs/insider selling persists; over 6–24 months, pipeline readouts and true commercial uptake (REDEMPLO sales cadence) are the decisive fundamentals; hidden dependency: current profitability heavily reliant on non-recurring licensing milestones, not recurring Rx demand.

Trade implications: For directional exposure prefer defined-risk structures: buy-call spreads or buy-on-dip equities with strict sizing; hedge market beta via short SPY or sector ETF (IBB) to isolate idiosyncratic upside. Options sellers can monetize inflated IV post-runup — sell/put spreads or covered calls against newly established long positions while targeting upside capture of +30–40% and limiting drawdown to 20%.

Contrarian angles: Consensus underweights commercialization execution and reimbursement risk — the market may be overpaying for milestone-driven revenue rather than sustainable product sales (compare post-approval trajectories of RNAi pioneer ALNY). If institutional holders begin systematic trimming, distribution can amplify a technical correction; mispricings show in elevated IV and gap-up returns without corroborating sequential sales growth, creating opportunities for volatility-selling and disciplined dip-buying.

Key Decisions for Investors

• Establish a 2–4% portfolio long position in ARWR on weakness: size buys into any pullback to <= $65–70, set a stop-loss at 20% below entry and a sell target of $95 (≈+30% from $73) within 3–6 months contingent on commercial sales cadence.
• If preferring defined risk, purchase a 12-month call spread (buy Jan 2027 $70 call, sell Jan 2027 $110 call) sized to 0.5–1% of portfolio notional to capture upside while capping premium outlay; reassess after Q1 sales/earnings release.
• Implement a market‑neutral pairing: go long ARWR 2% and short SPY 1.5% (or short IBB 1–1.5%) to remove broad beta and concentrate on idiosyncratic ARWR commercialization/catalyst risk; rebalance after 30–90 days or post major trial/commercial updates.
• If IV >60% in next 30–90 days, sell 30–45‑delta monthly calls (covered if long) or sell 45–60‑delta put spreads to collect premium; cap downside by limiting net exposure to <2% capital per trade and close if IV drops >25% or stock moves >+25%.